Several hundred units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the Food and Drug Administration.

Mavacamten was not found to benefit patients with symptomatic NYHA class II-III nonobstructive hypertrophic cardiomyopathy.

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

For patients with posterior circulation stroke, alteplase administered at 4.5 to 24 hours after onset increases frequency of functional independence.

Over the past 2 decades, stroke-related mortality among individuals with HIV has decreased, but racial and gender disparities continue to exist.

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

Engaging in physical activity concentrated within 1 to 2 days is associated with a similar reduction in mortality risk as active regular physical activity.

There are substantial rural-urban disparities in cardiometabolic risk factors and cardiovascular diseases among US adults.

Researchers have found that patients with stage B heart failure characteristics and type 2 diabetes have impaired functional capacity.

Federal cuts to funding could “decimate” medical research in the US, delaying cures and costing countless lives.

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.